In vitro study | LJI308 inhibits S6K1 with an IC 50 of 0.8 μM. LJI308 inhibits YB-1 phosphorylation in CRC cells at concentrations of 5 to 25 μM. In a dose kinetics experiment, LJI308, starting at 2.5 μM, inhibits YB-1 phosphorylation in the KRAS mutated TNBC cell line MDA-MB-231 by approximately 86%. LJI308 effectively blocks RSK and YB-1 phosphorylation after EGF stimulation and after irradiation in KRAS wild-type HBL-100 cells. LJI308 (1-10 μM; 96 hours) decreases cell viability by up to 90%. Cell Viability Assay Cell Line: HTRY-LT cell lines Concentration: 1-10 μM Incubation Time: 96 hours Result: Decreased cell viability by up to 90%. |